---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-035913"
form_type: "8-K"
ticker: "LPCN"
cik: "0001535955"
company_name: "Lipocine Inc."
filed_at: "2026-08-04T10:08:32+00:00"
generated_at: "2026-08-04T10:10:11.917893+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Lipocine Q2 net loss $2.6M; Phase 3 PPD trial misses primary endpoint

## Summary
- Net loss of $2.6M ($0.32 per share) vs $2.2M loss ($0.41 per share) in Q2 2025.
- Cash and investments $23.3M at June 30, 2026, up from $14.9M at Dec 31, 2025.
- Phase 3 trial of LPCN 1154 for PPD missed primary endpoint; post hoc analysis suggests efficacy; FDA meeting Q3 2026.
- TLANDO royalty revenue $190k in Q2 2026, up from $123k; UAE approval for TESTYRA (TLANDO) received July 8, 2026.
- New placebo-controlled trial for LPCN 1154 initiated to complement existing data.

## SEC filing metadata
- accession: 0001493152-26-035913
- form_type: 8-K
- ticker: LPCN
- cik: 0001535955
- company_name: Lipocine Inc.
- filed_at: 2026-08-04T10:08:32+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1535955/000149315226035913/0001493152-26-035913-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1535955/000149315226035913/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-035913
- JSON: https://secwatch.observer/filing/0001493152-26-035913.json
- Plain text: https://secwatch.observer/filing/0001493152-26-035913.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.